Award Data

DESCRIPTION (provided by applicant): Entamoebga histolytica is a protozoan parasite and the causative agent of amebiasis in humans. Intestinal amebiasis causes debilitating diarrhea and dysentery, while extraintestinal amebiasis occurs when the parasite migrates from the intestinal tract to organs throughout the body, most commonly the liver. The NIAID Blue Ribbon Panel on Biodefense Agents B&C ta ...

DESCRIPTION (provided by applicant): In the United States, about 80% of hospital patients require IV therapy and about 50% of IV lines fail due to infiltration, a clot in the cannula, an inflammatory response of the vein, or separation of the cannula from the vein. IV infiltration is usually accompanied by pain, erythema, and/or swelling at the cannula tip or the insertion site. Severe infiltratio ...

DESCRIPTION (provided by applicant): The principal objective of this application is to establish a new methodology for the early detection of abnormal lesions, whether pre-cancerous or cancerous, in breast imaging. Early detection is crucial to identifying lesions while they are still contained when the cure rate is near 100%. Existing mammography often does not identify lesions until significant ...

DESCRIPTION (provided by applicant): We propose to develop a novel dual FRET molecular beacons technology for living cell detection and analysis of cancer. Molecular beacons are dual-labeled oligonucleotide probes with a stem-loop hairpin structure. Hybridization of molecular beacons with target mRNAs corresponding to cancer markers results in fluorescence of the cell. Thus, cancer cells (brig ...

DESCRIPTION (provided by applicant): We propose to develop a novel dual FRET molecular beacons technology for living cell detection and analysis of cancer. Molecular beacons are dual-labeled oligonucleotide probes with a stem-loop hairpin structure. Hybridization of molecular beacons with target mRNAs corresponding to cancer markers results in fluorescence of the cell. Thus, cancer cells (brig ...

DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to develop a new therapy for the treatment of asthma. The desired outcome will be the identification of a therapeutic candidate to replace theophylline, a non-selective adenosine receptor antagonist that is effective in treating asthma, but limited by side effects, primarily insomnia, mediated by blockade the A1AR in the brain. ...

DESCRIPTION (provided by applicant): Ischemic injury of the brain is a major cause of death and morbidity, and often causes long term disability. NMDA receptor (NMDAR) blockers, particularly targeting the NR2B-subunit are neuroprotective in ischemic disease animal models. Unfortunately, most NMDAR antagonists have failed in clinical development as a result of unacceptable side effects such as memo ...

DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

DESCRIPTION (provided by applicant): Mitochondrial DNA (mtDNA) accumulates mutations with aging in human beings and animal models of accelerated mtDNA mutagenesis produce advanced aging phenotypes such as osteoporosis, cardiomyopathy, neurodegeneration, hair loss, anemia and reduced fertility. Though compelling, these animal models are insufficient to prove that mtDNA is responsible for aging phen ...